CRSP - CRISPR Therapeutics GAAP EPS of -$1.43 misses by $0.03 revenue of $0.5M misses by $24.67M
2024-05-08 16:57:43 ET
More on CRISPR Therapeutics
- Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
- Crispr Therapeutics: Now Is The Time To Buy
- TD Cowen says sickle cell therapies may get higher CMS payments
- Biotech Roundtable: Who will bring the next CRISPR drug to market?